Foundation Medicine and Merus Collaborate on RNA Platform for Targeting Neuregulin 1 Fusion Cancers
Portfolio Pulse from Benzinga Newsdesk
Foundation Medicine and Merus N.V. have announced a collaboration to develop an RNA platform as a companion diagnostic for Merus's bispecific antibody zenocutuzumab (Zeno) to treat neuregulin 1 fusion cancers.
August 28, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus N.V. collaborates with Foundation Medicine to develop an RNA platform for its bispecific antibody Zeno, targeting neuregulin 1 fusion cancers.
The collaboration with Foundation Medicine to develop a companion diagnostic for Zeno could enhance the effectiveness and marketability of Merus's treatment for NRG1+ cancers, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90